Feature

Support for medical marijuana transcends political affiliation


 

There is not much common ground between Republicans and Democrats these days, but both sides strongly supported the use of medical marijuana in a recent survey by the American Society of Clinical Oncology.

Survey: Support for medical marijuana crosses party lines

Overall support of medical marijuana among all 4,001 respondents was higher (84%) for use among cancer patients, but 76% also supported its use for any medical reason, according to data from the survey conducted for ASCO by the Harris Poll.

The differences in support between Republicans and Democrats were significant, but both parties were over 80% for marijuana use by cancer patients and over 70% for use for any medical reason. In both cases, the independents in between mirrored the overall population, with support at 84% and 76%, respectively, ASCO said.

Support for medical marijuana also was consistent based on the respondents’ cancer experience. For use by cancer patients, those who were current or previous patients were at 84%, caregivers (those providing unpaid care to an immediate family member or loved one with cancer) and other family members/loved ones were both at 87%, and those with no cancer experiences were at 82%, the survey results showed.

Use of marijuana for any medical reason was supported by 72% of current/previous patients, 79% of family members and loved ones, 80% of caregivers, and 74% of those with no cancer experience, ASCO reported.

In a question asked only of current or previous patients, 62% said that they are/were open to use of marijuana to alleviate cancer-related pain, nausea, or other symptoms, and 60% said that they wished they had more information about the benefits of medical marijuana use, according to the results of the survey, which was conducted online from July 9 to Aug. 10, 2019.

Recommended Reading

USPSTF recommendations on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer
MDedge Internal Medicine
Levothyroxine dose for checkpoint inhibitor toxicity may be too high
MDedge Internal Medicine
More evidence that statins reduce HCC risk
MDedge Internal Medicine
ACP: Low-risk adults aged 50-75 should undergo regular screening for colorectal cancer
MDedge Internal Medicine
U.S. deaths from preventable causes occur more often in rural areas
MDedge Internal Medicine
Lung cancer screening, early diagnosis still lower among blacks, Hispanics
MDedge Internal Medicine
Small nodules, big problems: AI's role in thyroid nodule diagnosis
MDedge Internal Medicine
Direct-acting antiviral treatment linked to lower mortality in patients with HCC history
MDedge Internal Medicine
Surgical staging improves cervical cancer outcomes
MDedge Internal Medicine
Nivolumab-ipilimumab combo has ‘robust’ clinical benefit in sorafenib-treated HCC patients
MDedge Internal Medicine